Clearside Biomedical (CLSD) Tops Q3 EPS by 2c

Clearside Biomedical (NASDAQ: CLSD) reported Q3 EPS of ($0.10), $0.02 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $1.04 million versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Prologis makes unsolicited bid for SEGRO, valued at £12.6 billion
• Mizuho Starts Sol Gel Technologies Ltd. (SLGL) at Outperform